Verrica Pharmaceuticals Strives for Nasdaq Compliance

Date:

The latest announcement is out from Verrica Pharmaceuticals ( (VRCA) ).

Verrica Pharmaceuticals Inc. finds itself temporarily non-compliant with Nasdaq’s independent director requirement following the immediate resignation of board member Craig Ballaron. The company has appointed Diem Nguyen to the Audit Committee, signaling steps toward rectifying the issue. Nasdaq has granted a cure period for compliance, which extends until the company’s next annual stockholders meeting or October 2, 2025, whichever comes first. If the meeting occurs before March 31, 2025, the company must comply by that date. Verrica Pharmaceuticals is confident it will meet the requirements within the provided timeframe.

See more data about VRCA stock on TipRanks’ Stock Analysis page.

Read more…

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Tampa RV giant Lazydays to delist from Nasdaq

Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...

Granite Geek: New Hampshire might get access to ‘balcony solar’

I had solar panels put on my roof six...

TSX Today: What to Watch for in Stocks on Monday, November 10

Despite firm gold and silver prices, Canadian stocks...

While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!

As market-wide fear grips the sector, the Binance Coin...